Japan’s Kyorin To License Diabetes Drug For Foreign Development
This article was originally published in PharmAsia News
Kyorin Pharmaceuticals of Japan plans to license its diabetes drug currently in Phase II trials for foreign development and sale, but pursue Japanese approval on its own. KRP-104 increases insulin secretion when blood sugar levels rise as a result of eating. Kyorin expects to complete Phase II trials in the United States this summer, but license the drug to a global company to take it through Phase II trials and then to market in other countries. The drug is still in Phase I trials in Japan. (Click here for more - a subscription may be required
You may also be interested in...
Firm supplying all-in-one multivitamin blends rather than packs of multiple pills has four-member advisory board including digital marketing and consumer product marketing specialists and a health care strategist.
UK-headquartered company gets further backing from Novo Ventures and other investors convinced of the potential of NLRP3 inhibitors.
Mylan and Pfizer’s Upjohn have revealed a key date for their merger to create Viatris, after the deal set for midway through the year was pushed back recently due to the coronavirus pandemic.